Outpatient Parenteral Antimicrobial Therapy Today

被引:130
作者
Paladino, Joseph A. [2 ,3 ]
Poretz, Donald [1 ]
机构
[1] Infect Dis Phys, Annandale, VA 22003 USA
[2] SUNY Buffalo, Buffalo, NY 14260 USA
[3] CPL Associates, Clin Outcomes Res, Amherst, NY USA
关键词
INTRAVENOUS ANTIBIOTIC-THERAPY; COMMUNITY-ACQUIRED PNEUMONIA; RESEARCH TEAM COHORT; ANTIINFECTIVE THERAPY; STAPHYLOCOCCUS-AUREUS; PRACTICE GUIDELINES; COST-ANALYSIS; OUTCOMES; HOME; OSTEOMYELITIS;
D O I
10.1086/653520
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Since its introduction in the 1970s, outpatient parenteral antimicrobial therapy (OPAT) has become a standard modality for patients with many infections requiring long-term intravenous antibiotic therapy. Delivery of OPAT may occur in physicians' offices, hospital clinics, specialized infusion centers, and currently most often, patient's homes, often self-administered. Patients are selected for OPAT by physicians familiar with both the course of their infections, their personal suitability for outpatient care, and the availability of reimbursement. OPAT is reportedly safe, effective, practical, and cost-effective. An OPAT Outcomes Registry contains information from >11,000 antibiotic courses administered from 1997 through 2000. Although a number of studies are purported to analyze the economic impact of OPAT on health care, a comprehensive, clinical outcomes-based pharmacoeconomic analysis, as described here, has, to our knowledge, yet to be done.
引用
收藏
页码:S198 / S208
页数:11
相关论文
共 46 条
[1]  
*AM HOSP ASS HOSP, 1999, EM TRENDS HOSP
[2]  
ANTONISKIS A, 1978, WESTERN J MED, V128, P203
[3]  
BERLIN LH, 1988, NY TIMES 0626
[4]   Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis:: evaluation of efficacy, tolerance and cost [J].
Bernard, L ;
El-hajj ;
Pron, B ;
Lotthé, A ;
Gleizes, V ;
Signoret, F ;
Denormandie, P ;
Gaillard, JL ;
Perronne, C .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2001, 26 (06) :445-451
[5]   Use of insurance claims data to assess outpatient antimicrobial therapy for gram-positive infections [J].
Carmeli, Y ;
Mozaffari, E .
PHARMACOTHERAPY, 2002, 22 (02) :55S-62S
[6]   COST-ANALYSIS OF A HOME INTRAVENOUS ANTIBIOTIC PROGRAM [J].
CHAMBERLAIN, TM ;
LEHMAN, ME ;
GROH, MJ ;
MUNROE, WP ;
REINDERS, TP .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1988, 45 (11) :2341-2345
[7]   Dalbavancin: a novel antimicrobial [J].
Chen, A. Y. ;
Zervos, M. J. ;
Vazquez, J. A. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (05) :853-863
[8]   Home intravenous antimicrobial infusion therapy: A viable option in older adults [J].
Cox, Amanda M. ;
Malani, Preeti N. ;
Wiseman, Stephen W. ;
Kauffman, Carol A. .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (05) :645-650
[9]   Financial impact of a home intravenous antibiotic program on a Medicare managed care program [J].
Dalovisio, JR ;
Juneau, J ;
Baumgarten, K ;
Kateiva, J .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (04) :639-642
[10]  
Das B, 2008, PAK J PHARM SCI, V21, P78